SOURCE: Ventana Medical Systems, Inc.

January 31, 2007 11:45 ET

First Symphony High Definition H&E Study Published

TUCSON, AZ -- (MARKET WIRE) -- January 31, 2007 --Ventana Medical Systems, Inc. (NASDAQ: VMSI) today announced the results of a multi-center study across 120 cases of prostatic carcinoma comparing Symphony High Definition H&E slide staining to routine H&E staining methods. The study, conducted by Dr. Jonathan Epstein of Johns Hopkins Hospital, concluded that, "The underdiagnosis of limited adenocarcinoma of the prostate on needle biopsy is one of the most frequent problems in urologic pathology. Although various IHC studies can aid in the diagnosis of prostate cancer, each has its false positives and negatives, and the cornerstone of establishing a diagnosis of prostate cancer rests on its H&E appearance. The Ventana Symphony H&E staining protocol consistently highlights nucleoli in cancer to a greater extent than routine H&E stains and may increase the likelihood of making a diagnosis of limited adenocarcinoma of the prostate in challenging cases."

The results of the study showed that in all 120 cases, the Symphony H&E stain was superior to the standard H&E with regard to visualization of nucleoli and demonstrated an approximate twofold increase in the identification of prominent nucleoli compared to conventional methods.

In addition to Johns Hopkins Hospital, the multi-center analysis included the Cleveland Clinic Foundation; University of Pittsburgh Medical Center; University of Maryland Medical Center; Quest Diagnostics; and Dianon Systems.

"We are very pleased with the results of this first study, which will be published in Modern Pathology and presented at the United States and Canadian Academy of Pathology (USCAP) meeting in March," stated Christopher Gleeson, Ventana President and CEO. "Demonstrating the Symphony's diagnostic and workflow value to laboratories and pathologists is important and we look forward to the outcomes from several additional studies to be undertaken with a focus on productivity and efficiency together with clinical utility," Gleeson further commented.


Ventana develops, manufactures, and markets instrument/reagent systems that automate tissue preparation and slide staining in clinical histology and drug discovery laboratories worldwide. The Company's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana's drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds.


This press release contains forward-looking statements within the meaning of the Federal Securities laws. These forward-looking statements are subject to numerous risks and uncertainties, and actual results may vary materially. Product development activities may not be as successful as we expect in terms of the timing of product availability to the market or customer rates of adoption. Other risks and uncertainties include risks associated with the development, manufacturing, marketing, and sale of medical products, competitive factors, general economic conditions, legal disputes, and government actions, and those other risks and uncertainties contained in our most recent Annual Report filed with the Securities and Exchange Commission (SEC) on Form 10-K, and all subsequent SEC filings. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis retrieval system (EDGAR) at We undertake no obligation following the date of this release to update or revise our forward-looking statements or to update the reasons actual results could differ materially from those anticipated in forward-looking statements. We caution you not to place undue reliance upon any such forward-looking statements, which speak only as of the date such statements are made. Past performance is not indicative of future results. We cannot guarantee any future operating results, activity, performance, or achievement.

Visit the Ventana Medical Systems, Inc. website at

Contact Information

  • Contact:
    Christopher M. Gleeson
    President and CEO
    (520) 229-3787

    Nick Malden
    Chief Financial Officer
    (520) 229-3857

    1910 E. Innovation Park Drive
    Tucson, Arizona 85755
    (520) 887-2155